SCHEMBL6852072

SCHEMBL6852072

O=[N+]([O-])Nc1ccccc1F

nearest known ligand 0.47

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 7/20 0.47
NPC1 O15118 5/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
MAPT P10636 6/20 0.46
MEN1 O00255 6/20 0.46
KMT2A Q03164 6/20 0.46
HTT P42858 4/20 0.44
MAPK1 P28482 3/20 0.42
LMNA P02545 2/20 0.42
L3MBTL1 Q9Y468 2/20 0.41
PSIP1 O75475 1/20 0.41
RORC P51449 1/20 0.41
GAA P10253 1/20 0.39
ALDH1A1 P00352 2/20 0.38
POLB P06746 1/20 0.38
ATM Q13315 1/20 0.38
CASP7 P55210 1/20 0.37
TDP1 Q9NUW8 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4063469 0.83 KMT2A (0.37) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL30335 0.74 NPC1 (0.49) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL31374378 0.74 MAPK1 (0.49) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL7208909 0.74 MAPK1 (0.49) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL11045869 0.74 MEN1 (0.43) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL950729 0.74 MAPK1 (0.60) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL45337 0.74 MAPT (0.47) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL2333439 0.74 HSD17B10 (0.48) RAB9ANPC1SMN1; SMN2MAPTKMT2A
Nitric Acid SCHEMBL20984275 0.74 RAB9A (0.47) RAB9ANPC1SMN1; SMN2MAPTMEN1
SCHEMBL11570570 0.74 ALDH1A1 (0.34) RAB9ANPC1SMN1; SMN2MAPTMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4719391-A2 TRIPLE KINASE INHIBITORS Unogen Biotech Ltd. (US) 2026-04-08 EP disclosed
US-20260085050-A1 TRIPLE KINASE INHIBITORS UNOGEN BIOTECH LTD (US) 2026-03-26 US disclosed
WO-2024249831-A2 TRIPLE KINASE INHIBITORS UNOGEN BIOTECH LTD. (US) 2024-12-05 WO disclosed
EP-3215499-B1 IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES EMERGENT VIROLOGY LLC (US) 2021-01-20 EP disclosed
CN-111655677-A Benzimidazole compounds as agrochemicals 瑞戴格作物保护公司 2020-09-11 CN disclosed
CN-111542517-A Benzimidazole compounds as agrochemicals 瑞戴格作物保护公司 2020-08-14 CN disclosed
US-10428022-B2 Iminosugars useful for the treatment of viral diseases EMERGENT VIROLOGY LLC (US) 2019-10-01 US disclosed
US-20180273473-A1 IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG INC. 2018-09-27 US disclosed
EP-3215499-A1 IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES Emergent Virology LLC (US) 2017-09-13 EP disclosed
WO-2016073652-A1 IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES UNITHER VIROLOGY, LLC (US) 2016-05-12 WO disclosed
US-6780998-B2 DEVELOPER-COUPLER SUBSTANCE COMBINATION HAIR DYES WELLA AKTIENGESELLSCHAFT (DE) 2004-08-24 US disclosed
US-20020189033-A1 Substituted 2-aminoalkyl-1,4diaminobenzene compounds and oxidation dye precursor compositions containing same WELLA INTERNATIONAL OPERATIONS SWITZERLAND SARL (CH) 2002-12-19 US disclosed
US-5685881-A Aromatic allylaminonitro compounds, hair dye compositions containing aromatic allylaminonitio compounds, and synthetic and natural fiber dyeing process HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1997-11-11 US disclosed
EP-0671900-B1 ALLYLAMINO-NITROAROMATES HENKEL KGAA (DE) 1996-08-14 EP disclosed
EP-0671900-A1 ALLYLAMINO-NITROAROMATES. HENKEL KGAA (DE) 1995-09-20 EP disclosed
WO-1994012149-A1 ALLYLAMINO-NITROAROMATES HENKEL KOMMANDITGESELLSCHAFT AUF AKTIEN (DE) 1994-06-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260085050-A1 TRIPLE KINASE INHIBITORS ALK, ERBB2, ERBB3 RAB9A 1264/4885NPC1 1543/4885SMN1; SMN2 3559/4885
US-10428022-B2 Iminosugars useful for the treatment of viral diseases GBA1, MAN2B1, GBA2 RAB9A 1251/4885NPC1 36/4885SMN1; SMN2 706/4885
US-20020189033-A1 Substituted 2-aminoalkyl-1,4diaminobenzene compounds and oxidation dye precursor compositions containing same DDT, CYP1B1, ALDH7A1 RAB9A 4496/4885NPC1 4319/4885SMN1; SMN2 4489/4885
US-20180273473-A1 IMINOSUGARS USEFUL FOR THE TREATMENT OF VIRAL DISEASES GBA1, MAN2B1, GBA2 RAB9A 1251/4885NPC1 36/4885SMN1; SMN2 706/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.